Search Results
- < Prev
1 of 1
- Next >
News Releases
-
May 23, 2013, 06:30 ET
OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer. This trial...
More news about: OncoGenex Pharmaceuticals, Inc.
-
May 22, 2013, 06:30 ET
OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a leader in the development of novel therapeutics to target mechanisms of treatment resistance in cancer, today announced that four trials of its investigational compounds, custirsen and OGX-427, will be presented as "Trials in Progress" posters...
More news about: OncoGenex Pharmaceuticals, Inc. , 49th Annual Meeting of the American Society of Clinical Oncology , American Society of Clinical Oncology
-
May 02, 2013, 16:00 ET
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter 2013 financial results. OGX-427 Program Update - In January 2013, the Company initiated the...
More news about: OncoGenex Pharmaceuticals, Inc. , Teva Pharmaceutical Industries Ltd.
-
Apr 11, 2013, 08:00 ET
OncoGenex Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Spruce clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled Phase 2 study evaluating OGX-427 in patients with previously untreated advanced non-squamous non-small...
More news about: OncoGenex Pharmaceuticals, Inc. , Teva Pharmaceutical Industries Ltd.
-
Mar 28, 2013, 16:01 ET
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference
BOTHELL, WA and VANCOUVER, March 28, 2013 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Future Leaders in the Biotech Industry Conference on Friday,...
More news about: OncoGenex Pharmaceuticals, Inc.
- < Prev
1 of 1
- Next >
Modify your Search
 |
Quickly search for PR Newswire releases by adding our plugin to your browser search |